# Clinical Trial Data Insights Report
## NEST 2.0 - Comprehensive Data Analysis

**Report Generated:** December 27, 2025  
**Data Source:** 23 Clinical Studies  
**Total Records Analyzed:** 400,000+

---

## Executive Summary

This report presents key insights from the analysis of clinical trial data across 23 studies. The analysis covers data quality issues, adverse event coding, drug coding, safety events, missing data patterns, and visit compliance. **Critical findings require immediate attention** to ensure data integrity and regulatory compliance.

---

## 1. Open Issues Analysis (EDRR)

### Key Metrics
| Metric | Value |
|--------|-------|
| Total Open Issues | **2,164** |
| Subjects Affected | 893 |
| Average Issues per Subject | 2.42 |
| Maximum Issues (Single Subject) | 17 |

### 🚨 Critical Insight: Study 16 Concentration

> **ALERT:** Study 16 accounts for **48.9% of all open issues** (1,059 out of 2,164) despite having only 208 subjects with issues.

**Top 3 Studies by Open Issues:**
1. **Study 16:** 1,059 issues (avg 5.09 per subject) - **CRITICAL**
2. **Study 23:** 457 issues (avg 3.39 per subject) - HIGH
3. **Study 22:** 277 issues (avg 1.04 per subject) - MODERATE

### Recommendations
- 🔴 **Immediate:** Conduct root cause analysis for Study 16's exceptionally high issue rate
- 🟡 **Priority:** Implement enhanced monitoring for Studies 23 and 16
- 🟢 **Ongoing:** Track issue resolution velocity across all studies

---

## 2. Adverse Event Coding (MedDRA)

### Key Metrics
| Metric | Value |
|--------|-------|
| Total AE Records | **66,858** |
| Coded Terms | 66,442 (99.4%) |
| Uncoded Terms | 416 (0.6%) |
| Require Coding | 416 |

### ✅ Positive Finding: High Coding Completion Rate

> **99.4% of adverse events are properly coded**, indicating strong medical coding processes.

### 🔍 Insight: Study Distribution Imbalance

**Top 3 Studies by AE Volume:**
1. **Study 4:** 30,140 records (45.1% of all AEs) - Requires dedicated coding resources
2. **Study 25:** 8,681 records (13.0%)
3. **Study 8:** 7,403 records (11.1%)

### Uncoded Terms Analysis
- **416 terms require immediate coding attention**
- Potential bottlenecks: Complex medical terminology, dictionary limitations
- Impact: May affect safety signal detection and regulatory submissions

### Recommendations
- 🔴 **Urgent:** Resolve 416 uncoded terms before next data lock
- 🟡 **Priority:** Allocate additional coding resources to Study 4
- 🟢 **Process:** Implement weekly coding completion dashboards

---

## 3. Drug Coding (WHODD)

### Key Metrics
| Metric | Value |
|--------|-------|
| Total Drug Records | **306,702** |
| Coded Terms | 305,714 (99.7%) |
| Uncoded Terms | 988 (0.3%) |

### ✅ Excellent Performance: Near-Complete Coding

> **99.7% coding completion rate** demonstrates robust drug coding processes.

### 🚨 Critical Insight: Study 21 Dominance

> **Study 21 contains 78.9% of all drug records** (242,103 out of 306,702)

**Implications:**
- Study 21 likely involves complex polypharmacy or concomitant medication tracking
- Higher risk of coding inconsistencies due to volume
- Resource allocation should prioritize Study 21

### Outstanding Coding Issues
- **988 uncoded drug terms** require attention
- Potential causes: Novel drugs, regional brand names, data entry errors

### Recommendations
- 🔴 **Action:** Clear 988 uncoded drug terms within 2 weeks
- 🟡 **Monitor:** Weekly QC reviews for Study 21 due to high volume
- 🟢 **Improve:** Establish synonym libraries for common brand name variations

---

## 4. Safety Events (eSAE Dashboard)

### Key Metrics
| Metric | Value |
|--------|-------|
| Total Safety Records | **17,098** |
| Review Completed | 11,688 (68.4%) |
| Pending for Review | 5,130 (30.0%) |
| Review in Progress | 266 (1.6%) |
| Review Ongoing | 14 (0.1%) |

### 🚨 Critical Insight: High Pending Review Rate

> **30% of safety events (5,130) are pending review** - This poses significant regulatory risk.

### Geographic Distribution

**Top 5 Countries by Safety Events:**
| Country | Records | % of Total |
|---------|---------|------------|
| USA | 1,312 | 7.7% |
| Spain | 582 | 3.4% |
| China | 452 | 2.6% |
| Brazil | 345 | 2.0% |
| Argentina | 335 | 2.0% |

### Study-Level Safety Concentration

> **Study 4 and Study 21 account for 92% of all safety events**

| Study | Safety Events | % of Total |
|-------|---------------|------------|
| Study 4 | 10,639 | 62.2% |
| Study 21 | 5,093 | 29.8% |
| Study 1 | 700 | 4.1% |
| Others | ~666 | 3.9% |

### Recommendations
- 🔴 **CRITICAL:** Clear 5,130 pending safety reviews immediately
- 🔴 **URGENT:** Prioritize Study 4 safety review backlog
- 🟡 **Resource:** Add dedicated safety reviewers for USA (highest volume country)
- 🟢 **Process:** Implement 48-hour SLA for new safety event reviews

---

## 5. Missing Pages Analysis

### Key Metrics
| Metric | Value |
|--------|-------|
| Total Missing Page Records | **5,524** |
| Records with Days Tracked | 1,498 |
| Average Days Missing | 52.9 days |
| Maximum Days Missing | **1,267 days** (>3.4 years!) |

### 🚨 Critical Insight: Aged Missing Data

> **174 pages (3.1%) have been missing for over 90 days** - indicating systemic data collection issues.

### Missing Duration Breakdown
| Duration | Count | % of Tracked |
|----------|-------|--------------|
| ≤30 days | 842 | 56.2% |
| 31-60 days | 341 | 22.8% |
| 61-90 days | 141 | 9.4% |
| >90 days | 174 | **11.6%** |

### Study-Level Missing Pages

**Top 3 Studies with Most Missing Pages:**
1. **Study 22:** 2,198 records (39.8%) - **CRITICAL**
2. **Study 24:** 1,019 records (18.4%) - HIGH
3. **Study 5:** 637 records (11.5%) - MODERATE

### Recommendations
- 🔴 **CRITICAL:** Investigate 1,267-day missing page - potential site/data integrity issue
- 🔴 **Urgent:** Remediation plan for Study 22's 2,198 missing pages
- 🟡 **Priority:** Root cause analysis for pages missing >90 days
- 🟢 **Process:** Weekly missing page reports to site monitors

---

## 6. Visit Compliance (Missing Visits)

### Key Metrics
| Metric | Value |
|--------|-------|
| Total Missing Visit Records | **871** |
| Records with Outstanding Days | 514 |
| Average Days Outstanding | 22.4 days |
| Maximum Days Outstanding | **373 days** |

### Visit Delay Distribution

| Delay Category | Count | % of Tracked |
|----------------|-------|--------------|
| ≤7 days | 189 | 36.8% |
| 8-30 days | 194 | 37.7% |
| 31-60 days | 67 | 13.0% |
| >60 days | 64 | **12.5%** |

### 🔍 Insight: Study 21 and Study 16 Visit Issues

**Top 3 Studies with Missing Visits:**
1. **Study 21:** 354 records (40.6%)
2. **Study 16:** 327 records (37.5%)
3. **Study 24:** 78 records (9.0%)

> Combined, Study 21 and Study 16 account for **78% of all missing visits**

### Recommendations
- 🔴 **Investigate:** 373-day outstanding visit - patient retention issue?
- 🟡 **Priority:** Enhanced follow-up protocols for Studies 21 and 16
- 🟢 **Improvement:** Automated visit reminder systems

---

## 7. Cross-Study Risk Assessment

### High-Risk Studies Requiring Immediate Attention

| Study | Risk Areas | Severity |
|-------|------------|----------|
| **Study 16** | Open issues (49%), Missing visits (38%) | 🔴 CRITICAL |
| **Study 21** | Drug records (79%), Safety events (30%), Missing visits (41%) | 🔴 CRITICAL |
| **Study 4** | AE records (45%), Safety events (62%) | 🔴 HIGH |
| **Study 22** | Missing pages (40%), Open issues | 🟡 MODERATE |
| **Study 24** | Missing pages (18%), Missing visits | 🟡 MODERATE |

### Studies with Good Data Quality
- Study 17, Study 10, Study 7 - Lower issue rates, better compliance

---

## 8. Data Quality Summary Dashboard

```
╔══════════════════════════════════════════════════════════════════╗
║                    DATA QUALITY SCORECARD                        ║
╠══════════════════════════════════════════════════════════════════╣
║  MedDRA Coding Completion     ████████████████████░  99.4%  ✅   ║
║  WHODD Coding Completion      ████████████████████░  99.7%  ✅   ║
║  Safety Review Completion     █████████████░░░░░░░░  68.4%  ⚠️   ║
║  Open Issue Resolution        ██████░░░░░░░░░░░░░░░  ~30%   🔴   ║
║  Missing Pages (>30 days)     ██░░░░░░░░░░░░░░░░░░░  11.9%  ⚠️   ║
║  Visit Compliance             █████████████████░░░░  87.5%  ✅   ║
╚══════════════════════════════════════════════════════════════════╝
```

---

## 9. Action Items Summary

### Immediate (This Week)
1. 🔴 Clear 5,130 pending safety reviews
2. 🔴 Root cause analysis for Study 16's 1,059 open issues
3. 🔴 Investigate pages missing >365 days
4. 🔴 Resolve 416 uncoded MedDRA terms

### Short-Term (Next 2 Weeks)
1. 🟡 Clear 988 uncoded WHODD drug terms
2. 🟡 Remediation plan for Study 22 missing pages
3. 🟡 Enhanced monitoring for Studies 4 and 21
4. 🟡 Site-level analysis for USA safety events

### Ongoing Improvements
1. 🟢 Weekly data quality dashboards
2. 🟢 Automated missing page alerts
3. 🟢 Coding turnaround SLAs
4. 🟢 Visit reminder automation

---

## Appendix: Data Sources

| Dataset | Records | Key Fields |
|---------|---------|------------|
| EDRR | 893 | Study, Subject, Issue Count |
| MedDRA | 66,858 | Coding Status, Form, Subject |
| WHODD | 306,702 | Drug Coding, Dictionary Version |
| eSAE | 17,098 | Review Status, Country, Site |
| Missing Pages | 5,524 | Days Missing, Visit, Form |
| Visit Projection | 871 | Days Outstanding, Visit Type |

---

